NCT07417124

Assess the Safety and Tolerability of SNS851 in Healthy Participants

A First-in-Human Study to Assess the Safety and Tolerability of Single and Multiple Doses of SNS851 in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 52 (estimated)
• Sponsor: Oneness Biotech Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.

Conditions

• Metabolic Disease

Interventions

Type	Name	Description
DRUG	SNS851	SNS851 is a potent siRNA treatment targeting metabolic diseases.
OTHER	Placebo	Normal saline

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-10-01
• Completion: 2026-10-01
• First posted: 2026-02-18
• Last updated: 2026-03-23

Locations

1 site across 1 country: Australia